Skip to main content

Table 1 Demographics and baseline characteristics of the pooled population

From: Impact of tanezumab on health status, non-work activities and work productivity in adults with moderate-to-severe osteoarthritis

 

Overall populationa

Subgroup who were employed (at baselineb)

Placebo (n = 514)

Tanezumab 2.5 mg (n = 514)

Tanezumab 5 mg (n = 517)

Placebo (n = 194)

Tanezumab 2.5 mg (n = 192)

Tanezumab 5 mg (n = 190)

Male, n (%)

161 (31.3)

171 (33.3)

173 (33.5)

73 (37.6)

85 (44.3)

64 (33.7)

Female, n (%)

353 (68.7)

343 (66.7)

344 (66.5)

121 (62.4)

107 (55.7)

126 (66.3)

Age, years, mean (SD)

62.5 (9.8)

63.2 (9.4)

63.4 (9.9)

56.3 (8.2)

57.7 (8.1)

57.4 (8.8)

White/Black or African American/Asian/other or unknown, n/n/n/n

403/60/47/4

423/43/43/5

418/50/42/7

146/24/22/2

148/22/20/2

140/22/26/2

Disease duration, years, mean (SD)c

8.7 (8.1)

7.9 (7.8)

8.3 (7.2)

7.5 (7.8)

7.4 (7.9)

7.5 (7.3)

Index joint, n (%)

 Hip

80 (15.6)

83 (16.1)

83 (16.1)

39 (20.1)

38 (19.8)

38 (20.0)

 Knee

434 (84.4)

431 (83.9)

434 (83.9)

155 (79.9)

154 (80.2)

152 (80.0)

Kellgren-Lawrence grade of index joint, n (%)d

 0

0

2 (0.4)

0

–

–

–

 1

0

1 (0.2)

0

0

1 (0.5)

0

 2

124 (24.1)

109 (21.2)

117 (22.7)

46 (23.7)

50 (26.0)

33 (17.5)

 3

221 (43.0)

232 (45.1)

226 (43.8)

94 (48.5)

78 (40.6)

94 (49.7)

 4

169 (32.9)

170 (33.1)

173 (33.5)

54 (27.8)

63 (32.8)

62 (32.8)

Average pain in the index joint (pain diary) score, mean (SD)e

7.01 (1.48)

6.97 (1.50)

7.00 (1.46)

6.99 (1.53)

6.99 (1.40)

7.10 (1.47)

WOMAC Pain score, mean (SD)f

6.9 (1.1)

6.9 (1.1)

6.9 (1.1)

7.0 (1.2)

6.9 (1.1)

7.1 (1.2)

WOMAC Physical Function score, mean (SD)f

7.0 (1.1)

7.0 (1.0)

7.0 (1.1)

7.0 (1.2)

7.0 (1.1)

7.2 (1.1)

PGA-OA score, mean (SD)f

3.5 (0.6)

3.5 (0.6)

3.5 (0.6)

3.5 (0.6)

3.5 (0.6)

3.5 (0.6)

Employment status, n (%)

 Employed

194 (37.7)

192 (37.4)

190 (36.8)

194 (100.0)

192 (100.0)

190 (100.0)

 Not employed

315 (61.3)

317 (61.7)

326 (63.1)

–

–

–

 Not known/data missing

5 (1.0)

5 (1.0)

1 (0.2)

–

–

–

EQ-5D-5L, mean (SD)f

0.48 (0.20)

0.48 (0.19)

0.47 (0.20)

0.47 (0.19)

0.49 (0.19)

0.46 (0.21)

EQ VAS, mean (SD)f

60.81 (19.26)

60.21 (20.13)

59.32 (18.83)

–

–

–

Percent activity impairment, mean (SD), n

67.88 (14.00), 509

67.94 (15.53), 509

68.53 (14.59), 516

65.72 (15.29), 194

63.80 (18.66), 192

66.58 (16.11), 190

Percent work time missed, mean (SD), n

–

–

–

7.05 (18.85), 169

6.64 (17.79), 176

7.75 (19.55), 166

Percent impairment while working, mean (SD), n

–

–

–

58.86 (20.90), 166

59.25 (21.61), 174

58.95 (20.17), 162

Percent overall work impairment, mean (SD), n

–

–

–

60.88 (20.84), 166

61.07 (21.78), 174

60.41 (20.51), 162

  1. aSome of these data were published previously [23]: Adapted from Schnitzer TJ, Berenbaum F, Conaghan PG, Dworkin RH, Gatti D, Yang R, et al. Single and composite endpoints of within-patient improvement in symptoms: pooled tanezumab data in patients with osteoarthritis. Rheumatol Ther. 2021;8:1759–74 (http://creativecommons.org/licenses/bync/4.0/)
  2. bThe number of patients employed at week 16 was n = 181 (placebo), n = 177 (tanezumab 2.5 mg), n = 176 (tanezumab 5 mg)
  3. cSample size n = 514 (placebo), n = 512 (tanezumab 2.5 mg), n = 515 (tanezumab 5 mg) for overall population, and n = 194 (placebo), n = 190 (tanezumab 2.5 mg), n = 189 (tanezumab 5 mg) for employed subgroup
  4. dSample size n = 514 (placebo), n = 514 (tanezumab 2.5 mg), n = 516 (tanezumab 5 mg) for overall population, and n = 194 (placebo), n = 192 (tanezumab 2.5 mg), n = 189 (tanezumab 5 mg) for employed subgroup
  5. eSample size n = 506 (placebo), n = 508 (tanezumab 2.5 mg), n = 511 (tanezumab 5 mg) for overall population, and n = 192 (placebo), n = 190 (tanezumab 2.5 mg), n = 188 (tanezumab 5 mg) for employed subgroup
  6. fSample size n = 513 (placebo), n = 513 (tanezumab 2.5 mg), n = 517 (tanezumab 5 mg) for overall population
  7. PGA-OA Patient’s global assessment of osteoarthritis, SD Standard deviation, VAS Visual analog scale, WOMAC Western Ontario and McMaster Universities Osteoarthritis Index
Back to article page

BMC Musculoskeletal Disorders

ISSN: 1471-2474

Contact us